- 专利标题: GLUCAGON-RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS OF USE THEREOF
-
申请号: US17538507申请日: 2021-11-30
-
公开(公告)号: US20220332781A1公开(公告)日: 2022-10-20
- 发明人: William Blackwell , Ved P. Srivastava , Mark A. Paulik , Andrew Young , Robert Neil Hunter, III , Steven Thomas Dock
- 申请人: Intarcia Therapeutics Inc.
- 申请人地址: US MA Boston
- 专利权人: Intarcia Therapeutics Inc.
- 当前专利权人: Intarcia Therapeutics Inc.
- 当前专利权人地址: US MA Boston
- 主分类号: C07K14/605
- IPC分类号: C07K14/605 ; C07K14/00 ; A61K38/26 ; A61K9/00
摘要:
This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
公开/授权文献
信息查询